Ascletis Pharma Inc.
ASCLF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Market Cap | $6,429 | $1,723 | $1,036 | $1,267 |
| - Cash | $1,580 | $866 | $343 | $330 |
| + Debt | $4 | $8 | $9 | $8 |
| Enterprise Value | $4,853 | $865 | $702 | $945 |
| Revenue | $1 | $1 | $0 | $10 |
| % Growth | -15.7% | – | -100% | – |
| Gross Profit | $0 | $1 | $0 | -$13 |
| % Margin | 11.2% | 57.3% | – | -125.2% |
| EBITDA | -$184 | -$225 | -$166 | -$222 |
| % Margin | -16,991.3% | -17,501% | – | -2,196.7% |
| Net Income | -$88 | -$171 | -$130 | -$128 |
| % Margin | -8,136.1% | -13,298.4% | – | -1,270.1% |
| EPS Diluted | -0.091 | -0.173 | -0.128 | -0.121 |
| % Growth | 47.2% | -34.9% | -6.1% | – |
| Operating Cash Flow | -$173 | -$138 | -$203 | -$76 |
| Capital Expenditures | $0 | -$2 | $0 | -$4 |
| Free Cash Flow | -$173 | -$140 | -$203 | -$81 |